Alimera Sciences (ALIM)
(Delayed Data from NSDQ)
$5.59 USD
+0.02 (0.36%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $5.58 -0.01 (-0.18%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Price, Consensus and EPS Surprise
ALIM 5.59 +0.02(0.36%)
Will ALIM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALIM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALIM
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates
ALIM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Biotech Stock Roundup: ALNY Up on Study Success, ALIM on Merger News & Other Updates
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Other News for ALIM
ALIM Stock Earnings: Alimera Sciences Misses EPS, Beats Revenue for Q2 2024
Alimera Sciences GAAP EPS of -$0.06, revenue of $27M
Alimera Sciences: Q2 Earnings Snapshot
Alimera Sciences Reports Second Quarter 2024 Results
Alimera Sciences reports Q2 EPS (6c), consensus (4c)